Arianna Marinello, MD
@AriMarinel
Followers
431
Following
658
Media
13
Statuses
72
Medical oncologist at Gustave Roussy & PhD student at Université Paris-Saclay Precision medicine for lung cancer✨ Cellular therapy and innovative treatments ☀️
Paris, France
Joined January 2022
Excited to share our article out in @JAMAOnc. The first to report the expression of membrane targets in RET+ NSCLC in a wide international cohort . Have a look:. @GustaveRoussy @CarisLife
🚨 New insights in #RETpositive #LungCancer:.RET+ NSCLC often express MET & TROP2, moderately HER3 & EGFR, and rarely HER2. ➡️ Multiple membrane targets may co-exist.🧬 Dynamic changes post-treatment — fresh biopsy recommended.💡 Supports ADC & bispecific antibody trials
0
6
23
Proud of being part of these amazing research group in @GustaveRoussy, made of great professionals and mentors.
Great "CLUB031" meeting this morning with our young talents and @BenjaminBesseMD to discuss progress on the translational studies they are brilliantly carrying out at @GustaveRoussy ! What a pleasure to accompany them in their career in thoracic oncology. @ClaudiaParisi18
0
0
9
RT @Al3ssandroRusso: The use of liquid biopsy can allow a better selection of NSCLC patients candidate to IO or Chemo-IO. Very interesting….
0
13
0
RT @FilippoDallOlio: What happens in the tumor and in the host when tumor burden increases? Could we use tMTV to decide when intensify the….
0
2
0
RT @GustaveRoussy: 🏆 Un grand bravo à Dr Antonio di Meglio, Dr Cédric Pobel, Dr Adèle Bonato, Dr Adrien Rousseau, Dr Arianna Marinello pour….
0
8
0
RT @GustaveRoussy: 🔹@GustaveRoussy à l'#ESMO24 . Les experts de l'institut sont présents pour leurs sessions poster. 💪. Mora Guardanamie, A….
0
8
0
RT @LodovicaZullo: From the largest RET-registry, a huge multicentric effort, @AriMarinel presents outcomes to inhibitors/chemo in RET+ adv….
0
3
0
The time for a practice-changing trial in locally advanced SCLC has come! . 🏆.In the ADRIATIC trial: significant OS benefit with durvalumab consolidation versus placebo after CTRT:.- 55.9 versus 33.4 months OS at the first interim analysis. #ASCO24
0
2
6
One-minute applause and standing ovation for the PFS LAURA in today plenary session at #ASCO24. 🏆 Consolidation therapy with osimertinib in unresectable stage III NSCLC improves PFS with an outstanding HR of 0.16. What a great time to cure lung cancer patients!
0
1
5
Interesting work presented by @mihaela_aldea at @AACR Annual Meeting 2024 ✨✨✨. @GustaveRoussy and @lifen_fr collaborate help data collection and facilitate clinical research . Come and have a look at her poster in section #36 board #29. #AACR
0
1
16
Great work on blood based NGS in head and neck carcinoma presented at @AACR Annual Meeting by @FilippoDallOlio from @GustaveRoussy . Board #10 section #40
0
0
10
RT @FAndreMD: We know how will be the next Research Building @GustaveRoussy (Q1 2027).32 000 m2 , 60 research teams in 15 Centers, 15 core….
0
14
0
RT @BenjaminBesseMD: Ceralasertib (ATR kinase inhibitor) for 7 days + durvalumab q4w: a promising combo post chemo-IO in pts with advanced….
nature.com
Nature Medicine - In the phase 2 HUDSON study, patients with advanced non-small-cell lung cancer received anti-PD-L1 combined with biomarker-guided therapy targeting ATR kinase, PARP, STAT3 or...
0
35
0
RT @JordiRemon: We’ll start 2024 with this ttx algorithm for NSCLC🫁including non-metastatic NSCLC.Pending Qx💡:.✏️Will ADC overcome docetaxe….
0
74
0
RT @GustaveRoussy: 🔹 @GustaveRoussy à l'#ESMO2023 🔹. Découvrez les posters des experts de l'institut à @myESMO 👇. 🔸 Dr Isabelle Borget.🔸 Dr….
0
4
0
Incredibily amazing discussion conducted by @BenjaminBesseMDtk conclude this exciting plenary session on #NSCLC with rare alterations ->.The (un)necessary trials. So proud of being part of his motivated team!
0
0
9
What a great time to study Ret+ tumors .Practice changing data for #NSCLC and MTC presented at #ESMO23 presidential symposium . Selpercatinib > cabozantinib or vandetanib in Ret+ medullary thyroid carcinoma . Selpercatinib > chemo-io in 1st line for Ret+ NSCLC .@RETpositive
0
3
7
RT @HendriksLizza: Is there a role for ADC in EGFR+ metastatic NSCLC? HERTHENA-Lung01 patritumab deruxtecan data are promising, although ma….
ascopubs.org
0
8
0